ArticleJournal of orthopaedics2025
Prognostic factors for disease progression of central high-grade conventional osteosarcoma of the appendicular skeleton: Single-centre experience within South Africa with minimum 3-year follow-up.
Article in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disease progression (DP) of osteosarcomas, albeit with aggressive treatments, hinders improving survival. The DP patterns are unique in low- and middle-income countries like South Africa. We determine the prognostic factors associated with disease progression (DP) of the appendicular skeleton's central high-grade conventional osteosarcoma (COS). Methods: This is a retrospective study of 77 patients, with a minimum 3-year follow-up period diagnosed with histological biopsy-confirmed COS. Descriptive statistics, Cox proportional regression modelling, and the Kaplan-Meier method were employed for the analysis. Results: DP occurred in 75 % of patients (58/77), either as a local progression - LP 32 % (25/77), systemic progression - SP 61 % (47/77) or both 32 % (24/77). In the univariate analysis, the factors associated with DP were proximal humerus tumor site (hazard ratio [HR] 2.48; 95 % confidence interval [CI], 1.02 to 6.04; p < 0.046), metastasis at diagnosis (HR 1.91; 95 % CI, 1.10 to 3.32; p < 0.022), multiple metastatic lesions (HR 2.58; 95 % CI, 1.13 to 5.88; p < 0.024), curative treatment (HR 0.33; 95 % CI 0.17 to 0.62; p < 0.001), palliative treatment (HR 2.17; 95 % CI 1.24 to 3.78; p < 0.007), and wide surgical resection (HR 0.48, 95 % CI 0.27 to 0.86; p < 0.013). On multivariate analysis, only age >19 years was an independent risk factor (HR 1.04; 95 % CI 1.00 to 1.08; p < 0.034). The median survival time was 24 months, with an overall survival (OS) of 57.1 % at 3 years. The projected Kaplan- Meier 5-year OS rate was 29.78 %, with a progression-free survival (PFS) rate of 10.28 % (HR 0.76; 95 % CI 0.52 to 1.112; p < 0.128). Conclusion: In this series of central high-grade conventional osteosarcoma of the appendicular skeleton from South Africa, we observed a uniquely high proportion of disease progression (DP). Age >19, metastatic disease, and no chemotherapy response yielded poor outcomes; in contrast, wide surgical resection is beneficial. Further elucidation is needed at a larger scale in this region. Study evidence level: IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.